foscarnet / Generic mfg. - LARVOL DELTA

CMV reactivation under foscarnet prophylaxis in cord blood transplantation: Increased NRM without impact on relapse or survival (ASH 2025) - "Prophylactic administration of letermovir was not performed. Tacrolimus and mycophenolate mofetil were used for GVHD prophylaxis... In CBT with early post-transplant prophylactic administration of FOS, CMV reactivation was associated with increased NRM, although no significant impact on relapse or OS was observed. CMV disease had a substantial negative impact on NRM and OS, underscoring the importance of timely intervention."

Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • CNS Disorders • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Nephrology • Pneumonia • Respiratory Diseases • Transplantation

Epidemiology, risk factors, and outcomes of cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplantation: A retrospective observational single-centre study from western India (ASH 2025) - "While pre-emptive therapy has reduced CMV disease, reactivation remains common, particularly in alternate donor transplants and resource-limited settings where access to newer antivirals like letermovir is limited...Serotherapy type did not impact overall reactivation, but early reactivation was significantly higher with Grafalon vs. Thymoglobulin (90% vs. 33.6%, p<0.001)...Adverse effects included neutropenia (ganciclovir/valganciclovir) and nephrotoxicity (foscarnet/cidofovir)... This single-centre study demonstrates a high CMV reactivation rate (89.7%) in a high-seroprevalence Indian cohort, especially in alternate donor and PTCy-treated patients. While CMV disease was rare due to effective surveillance and pre-emptive therapy, recurrence and antiviral toxicity were common. The type of serotherapy influenced early reactivation risk."

Retrospective data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Immunology • Neutropenia • Transplantation

Persistent hyponatremia as a distinctive feature of HHV-6B encephalitis in pediatric hematopoietic stem cell transplant recipients: A case series (ASH 2025) - "All five patients were administered antiviral therapy comprising ganciclovir, foscarnet, and intravenous immunoglobulin. Persistent hyponatremia may act as a distinctive clinical indicator of HHV-6B encephalitis in pediatric patients undergoing HSCT. The underlying mechanisms require further investigation."

Clinical • IO biomarker • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Cardiovascular • Chronic Myelomonocytic Leukemia • CNS Disorders • Dermatology • Endocrine Disorders • Epilepsy • Heart Failure • Hematological Malignancies • Infectious Disease • Juvenile Myelomonocytic Leukemia • Leukemia • Movement Disorders • Myelodysplastic Syndrome • Nephrology • Pediatrics • Pruritus • Rare Diseases • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • Transplantation • CD7

Efficacy of iptacopan in treatment of transplant-associated thrombotic microangiopathy (TA-TMA) post-allogeneic hematopoietic stem cell transplantation: A case series analysis (ASH 2025) - "Case III (28M, MDS-LB) . Baseline Characteristics Diagnosis Severe Aplastic Anemia (SAA) Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) Myelodysplastic Syndrome-Low Blast (MDS-LB) Pre-Treatment Labs - WBC: ↓ (2.13×10⁹/L) - HGB: 65g/L↓ - PLT: 4×10⁹/L↓↓ - ALT/AST: ↑ (44.56/50.96 U/L) - WBC: ↓ (3.73×10⁹/L) - HGB: 44g/L↓↓ - PLT: 19×10⁹/L↓ - PT/INR: ↑ (24.8s/2.17) - WBC: ↑ (15.42×10⁹/L) - HGB: 105g/L↓ - ALT/AST: ↑ (35.49/47.32 U/L) - D-dimer: 3.56 mg/L↑ Complications CMV viremia, TA-TMA, intestinal GVHD, heart failure EBV infection, TA-TMA, intestinal GVHD EBV viremia, liver GVHD, intestinal GVHD, TA-TMA New Drugs Used Iptacopan, Vedolizumab Iptacopan Iptacopan, Vedolizumab, Ruxolitinib Post-Treatment Trends Blood Routine - WBC/HGB/PLT: Continued fluctuations (no stabilization) - PLT: ↑ (improvement) - WBC/HGB: Partial stabilization - WBC: Stabilized - HGB/PLT: Gradual improvement Liver Function - ALT/AST: Persistent fluctuations..."

Clinical • Aplastic Anemia • Bone Marrow Transplantation • Cardiovascular • Congestive Heart Failure • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Heart Failure • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Myelodysplastic Syndrome • Transplantation

Single-center retrospective analysis of maribavir in the treatment of refractory and drug-intolerant cytomegalovirus viremia and cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation (ASH 2025) - P3 | "Maribavir, a novel anti-CMV agent, exhibits multimodal anti-CMV activity without cross-resistance to ganciclovir or foscarnet...Fifty patients received letermovir for CMV prophylaxis...The 1-year overall survival rate was 86.5% (95% CI: 74.7%–98.4%). Conclusion Maribavir demonstrated high efficacy and a favorable safety profile in treating refractory or drug-intolerant CMV viremia and CMV disease post- allo HSCT, characterized by rapid viral clearance (shortmedian time to response) and minimal adverse effects."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Cutaneous T-cell Lymphoma • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Nephrology • Pneumonia • Respiratory Diseases • Septic Shock • T Cell Non-Hodgkin Lymphoma • Transplantation

Positive outcomes associated with stem cell transplantation in pediatric/AYA patients who receive FLAG-IDA-venetoclax for high-risk AML (ASH 2025) - "Background : BCL-2 inhibitors like venetoclax have demonstrated encouraging remission rates whencombined with fludarabine, cytarabine, idarubicin, and G-CSF (FLAG-IDA), enabling more patients toproceed to stem cell transplantation (SCT)...All patients received a busulfan/fludarabine-basedconditioning regimen and received post-transplant cyclophosphamide and tacrolimus as GVHDprophylaxis...Two patients relapsed following HSCT at a median time of 203 days (196-209days), including the patient undergoing SCT with positive MRD and a patient with very high risk acutemegakaryoblastic leukemia who relapsed following cessation of a folate receptor 1-targeted antibodydrug conjugate (STRO-002) due to adverse effects...One patient experienced CMV reactivation 28 daysafter SCT with peak level of 338 IU/mL requiring IV foscarnet, 1 patient experienced MRSA bacteremia onday 10 following SCT treated with appropriate antibiotic coverage, and 1 patient experienceddisseminated..."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Pediatrics • Transplantation • CD8 • FOLR1

Maribavir for cytomegalovirus infections after hematopoietic stem cell transplantation: A real world comparative cohort study (ASH 2025) - "No treatment-relatedadverse events were observed during therapy.Nineteen patients received first-line maribavir for post-HSCT CMV infection, while 20 control patientsreceived other first-line regimens (12 predominantly foscarnet; 8 received combination therapy includingganciclovir or letermovir). In real-world, maribavir demonstrated rapid, effective, and safe clearance of CMV viremia inHSCT recipients. The comparative cohort study demonstrates comparable CMV clearance rates betweenfirst-line maribavir and conventional antiviral regimens in HSCT recipients. Notably, maribavir wasassociated with a clinically relevant 5-day reduction in median time to viral clearance (7 vs 12 days)."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Transplantation

Recurrence of acyclovir-resistant herpes encephalitis in an immunocompromised patient: A case report. (PubMed, World J Clin Cases) - "ARHE recurred in the patient following remission; therefore, it is necessary to discuss the length of the treatment period."

Journal • CNS Disorders • Hematological Disorders • Herpes Simplex • Infectious Disease • Movement Disorders

Shanghai Fosun Pharmaceutical announced that its subsidiary, Guilin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration of Foscarnet Sodium Injection. (TipRanks) - "This approval allows the drug to be used for treating cytomegalovirus retinitis in AIDS patients and acyclovir-resistant herpes simplex virus infections in patients with compromised immune systems, potentially strengthening the company’s position in the pharmaceutical market."

China approval • Cytomegalovirus Infection • Infectious Disease

Effect of Prophylactic Administration of Foscarnet for HHV-6 Encephalitis in Adult Single Cord Blood Transplantation. (PubMed, Transpl Infect Dis) - "Foscarnet prophylaxis was not significantly associated with a reduced incidence of HHV-6 encephalitis after UCBT, whereas high-dose steroid exposure was a risk factor. Notably, a lower incidence of encephalitis with foscarnet prophylaxis was observed in the low-dose steroid subgroup, although this finding requires confirmation in larger cohorts."

Journal • Bone Marrow Transplantation • CNS Disorders • Transplantation

PRIOH-1: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (clinicaltrials.gov) - P3 | N=158 | Completed | Sponsor: AiCuris Anti-infective Cures AG | Active, not recruiting ➔ Completed

Trial completion • Herpes Simplex • Infectious Disease

Cytomegalovirus and Crohn's disease as competing causes of small bowel inflammation after double-lung transplantation. (PubMed, Eur Clin Respir J) - "CMV infection was identified in intestinal biopsies and initially managed with two courses of valganciclovir. Due to persistent symptoms, genotypic analysis was performed, revealing UL97 mutations conferring ganciclovir resistance. Sequential therapy with foscarnet, maribavir, and letermovir achieved virological clearance, but diarrhea persisted...The patient was commenced on standard biological therapy for Crohn's disease, resulting in marked clinical improvement and recovery. This case illustrates the diagnostic challenge of distinguishing CMV enteritis from de novo Crohn's disease and determining the primary driver of the clinical presentation."

Journal • Crohn's disease • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Mucositis • Respiratory Diseases • Solid Organ Transplantation • Transplantation

Reversion of Val(Ganciclovir)-Resistance-Associated Mutations in Two SOT Patients with Mismatched Serostatus for CMV (D+/R-). (PubMed, Viruses) - "Following CMV DNA suppression, secondary prophylaxis with letermovir and val(ganciclovir) was initiated...Therapy was then switched to foscarnet, which was suspended due to renal failure, and then to maribavir...Detecting gene mutations that confer drug resistance is crucial for managing antiviral therapy when virological response is lacking. In our cases, the reversion of (va)ganciclovir-resistance mutations occurred after drug withdrawal, a previously unreported finding."

Journal • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Immunology • Renal Disease • Solid Organ Transplantation • Transplantation

Multifactorial Myeloneuropathy and HHV6 Encephalomyelitis Following Allogeneic Transplant in a Patient with Secondary AML (SNO 2025) - P1 | "Superimposed viral infections such as HHV6 further complicate the clinical picture.Case Presentation:A 31-year-old woman with secondary AML arising from CML (MECOM rearrangement, complex karyotype) underwent allogeneic stem cell transplant from a 10/10 HLA matched unrelated donor on clinical trial (NCT03802695) following thiotepa, busulfan, and fludarabine conditioning with ex vivo engineered graft (Naive T cell depleted; OrcaQ graft) with no post HCT immunosuppression...She was treated empirically with B12/B9/B6, dextromethorphan, SAM, leucovorin, IVIG, steroids, and plasma exchange without neurological improvement.Subsequent CSF demonstrated high HHV6 viral load and elevated protein and HHV6 viremia. She started on foscarnet...This case highlights a multifactorial neurologic syndrome involving myeloneuropathy and encephalitis, likely due to overlapping neurotoxicity from intrathecal chemotherapy, craniospinal radiation, and HHV6. Serial CSF and imaging studies..."

Clinical • Acute Myelogenous Leukemia • CNS Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Pain • Transplantation • Urinary Incontinence • Urology • MBP • MECOM

Anti-Infective-Associated AKI: A Narrative Review of the Epidemiology, Mechanisms, Risk Factors, Biomarkers, Clinical Course, Monitoring, Prevention, and Therapeutic Strategies. (PubMed, Antibiotics (Basel)) - "This narrative review addressed and updated different aspects of anti-infective-associated AKI, including amphotericin B, cidofovir, foscarnet, polymyxins, vancomycin, and aminoglycosides. Currently, there is no definitive treatment modalities for the management of AKI with anti-infectives. Therefore, supportive care is the mainstay of treatment."

Biomarker • Journal • Review • Acute Kidney Injury • Critical care • Inflammation • Nephrology • Renal Disease • CST3 • KIM1 • LCN2

Multifactorial Myeloneuropathy and HHV6 Encephalomyelitis Following Allogeneic Transplant in a Patient with Secondary AML (WFNOS 2025) - P1 | "Superimposed viral infections such as HHV6 further complicate the clinical picture.Case Presentation:A 31-year-old woman with secondary AML arising from CML (MECOM rearrangement, complex karyotype) underwent allogeneic stem cell transplant from a 10/10 HLA matched unrelated donor on clinical trial (NCT03802695) following thiotepa, busulfan, and fludarabine conditioning with ex vivo engineered graft (Naive T cell depleted ; OrcaQ graft) with no post HCT immunosuppression...She was treated empirically with B12/B9/B6, dextromethorphan, SAM, leucovorin, IVIG, steroids, and plasma exchange without neurological improvement.Subsequent CSF demonstrated high HHV6 viral load and elevated protein and HHV6 viremia. She started on foscarnet...This case highlights a multifactorial neurologic syndrome involving myeloneuropathy and encephalitis, likely due to overlapping neurotoxicity from intrathecal chemotherapy, craniospinal radiation, and HHV6. Serial CSF and imaging studies..."

Clinical • Acute Myelogenous Leukemia • CNS Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Pain • Transplantation • Urinary Incontinence • Urology • MBP • MECOM

Impact of Early Anti-Cytomegalovirus Therapy on the Incidence of Chronic Graft-Versus-Host Disease (ASH 2023) - "Ganciclovir (GCV) and foscarnet (FCN) are essential intravenous anti-CMV agents...We excluded patients who received FCN, GCV, valganciclovir, or letermovir as prophylactic therapy; those who began anti-CMV therapy before the day of transplantation; those who received both FCN and GCV; those who underwent T cell-depleting treatment... In this study, patients requiring early anti-CMV therapy were at a high risk of chronic GVHD, primary due to their increased incidence of acute GVHD. Remarkably, FCN could potentially mitigate the incidence of chronic GVHD for them. Especially, FCN would be beneficial for male recipients of female donor transplants who are typically at high risk for chronic GVHD."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Oncology • Transplantation

Clinically Significant CMV Infection in Allogeneic Stem-Cell Transplant Recipients: A Single Center Experience (ASH 2023) - "Graft-versus-host disease (GvHD) prophylaxis used in the non-haploidentical group was cyclosporine and short-course methotrexate while haploidentical recipients received cyclosporine, mycophenolate mofetil, and post-transplant cyclophosphamide. Letermovir prophylaxis was accessible for use for high-risk patients from February 2022...Foscarnet was the preferred first-line pre-emptive treatment option for patients during cytopenia... This is the first report from Qatar to report CMV infection post-allogeneic stem cell transplantation. Future in-depth analysis of our population and treatment responses is needed."

Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Transplantation

Adoptive Transfer of CMV-Specific TCR-T Cells for the Treatment of CMV Infection after Haploidentical Hematopoietic Stem Cell Transplantation (ASH 2023) - P1 | "The other two patients who initially didn't completely respond to CMV-TCR-T cell therapy had salvage ganciclovir and foscarnet administration and then had rapid CMV clearance. Our study firstly showed CMV-targeting TCR-T cell as a highly feasible, safe and effective first-line preemptive treatment for CMV reactivation after haploidentical PBSCT."

Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation

Characteristics of Acyclovir-Resistant Herpes Simplex Virus Infection in Hematological Patients. (PubMed, J Oral Pathol Med) - "Dentists play a key role in detecting acyclovir resistance through persistent oral HSV lesions, emphasizing early recognition, referral, and supportive care."

Journal • Acute Myelogenous Leukemia • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Herpes Simplex • Infectious Disease • Leukemia • Oncology • Transplantation

Role of Cytomegalovirus (CMV) Immunoglobulin in Managing Multidrug-Resistant CMV Infection in a Kidney Transplant Recipient (KIDNEY WEEK 2025) - "He received induction with thymoglobulin and maintenance immunosuppression with tacrolimus, MMF, and prednisone. Prophylaxis included valganciclovir (VGCV) and TMP-SMX...Despite VGCV therapy and MMF reduction, viral load rebounded to 94,600 IU/mL with resistance to VGCV and cidofovir. Maribavir (MBV) was initiated, resulting in temporary improvement, but viremia rebounded to 404,000 IU/mL...Foscarnet (FOS) was started but failed to reduce viremia...At seven months, he was discharged on letermovir (LTV), but viremia rose to 40,200 IU/mL by ten months...While not curative, CMV-Ig appeared to modulate disease activity, especially when standard options were exhausted or unavailable. This case underscores the importance of adherence, timely resistance testing, and the potential role of immunotherapeutics like CMV-Ig in refractory CMV management."

Clinical • Cardiovascular • Chronic Kidney Disease • Cytomegalovirus Infection • Diabetes • Fibrosis • Gout • Hematological Disorders • Hepatology • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Leukopenia • Liver Cirrhosis • Metabolic Disorders • Rheumatology • Transplantation

New Insights in Current Practice in the Management of DNA Viruses in Children Following Allogeneic HSCT at EBMT Centers (ASH 2024) - "Acyclovir/valacyclovir is the preferred prophylaxis in all centers...Ganciclovir is used for first line preemptive treatment in 53 centers (78%). Foscarnet is used as second line in 59 centers (87%). CMV viral resistance testing is available in 51 (75%) centers, using PCR in 27, NGS in 15 and/or Sanger sequencing in 11 centers.Rituximab (RTX) is considered for use as EBV prophylaxis in 24/68 (35%) centers, mostly for haplo TCD HSCTs (17/24; 71%), followed by haplo PTCY (8/24; 33%)...Prophylactic Letermovir is provided increasingly ahead of publications and approval. RTX is considered for use as EBV prophylaxis mostly in haplo HSCT settings. Addressing the causes of deviations from guidelines in routine practice may help improve the management of these viruses.*On Behalf of the European Society for Blood and Marrow Transplan tation (EBMT) Infectious Diseases Working Party (IDWP) and Pediatric Diseases Working Party (PDWP)."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Pediatrics

CD7.Pebl-CART for Patients with Relapsed/Refractory (r/r) T-Cell Acute Lymphoblastic Leukemia (T-ALL) (ASH 2024) - P1/2 | "Final drug products (DP) were cryopreserved and patients were treated with a single infusion after lymphodepletion including fludarabine and cyclophosphamide (30 mg/sqm/d for 4 days and 60 mg/kg/d for 2 days, respectively). All patients received letermovir as prophylaxis against CMV reactivation...Adenovirus reactivation was detected in 2 patients in both blood and stools and was successfully treated with twice-a-week infusions of cidofovir. BK virus infection causing hemorrhagic cystitis occurred in 2 patients, and CMV reactivation in 1 patient (successfully treated with foscarnet)...The role of allo-HSCT as consolidation remains to be determined. A phase I/II clinical trial to confirm these promising results is active and currently enrolling at our Institution (NCT06064903)."

Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Anemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology • Pediatrics • Pneumonia • Respiratory Diseases • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • Thrombocytopenia • CD7

RAC1 Directly Phosphorylates Both PKM2 and FBP1 to Promote Radioresistance in Hepatocellular Carcinoma. (PubMed, Mol Ther) - "Additionally, combining RT with the FDA-approved drug foscarnet sodium, which inhibits RAC1 activity, significantly improves therapeutic outcomes in vivo. These findings identify RAC1 as a key regulator of radioresistance and a potential therapeutic target in HCC."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor • PKM • RAC1

Acute Retinal Necrosis Caused by VZV and EBV Co-Infection in Patient with Hodgkin Lymphoma History (PubMed, Harefuah) - "Intravenous acyclovir and intravitreal foscarnet injections and systemic prednisone were started. ARN caused by co-infection with VZV and EBV can by treatment-resistant, especially in immunosuppressive patients. Patients can benefit from early detection and intervention and frequent follow-up."

Journal • Epstein-Barr Virus Infections • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Ocular Infections • Ocular Inflammation • Oncology • Ophthalmology • Pain • Retinal Disorders • Uveitis • Varicella Zoster • Vasculitis